GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Total Current Liabilities

OTLK (Outlook Therapeutics) Total Current Liabilities : $48.24 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Outlook Therapeutics's total current liabilities for the quarter that ended in Dec. 2024 was $48.24


Outlook Therapeutics Total Current Liabilities Historical Data

The historical data trend for Outlook Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Total Current Liabilities Chart

Outlook Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.89 6.75 19.73 46.73 42.55

Outlook Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.97 54.08 42.55 42.55 48.24

Outlook Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Outlook Therapeutics's Total Current Liabilities for the fiscal year that ended in Sep. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=12.05+29.491
+Other Current Liabilities+Current Deferred Liabilities
=1.013+0
=42.55

Outlook Therapeutics's Total Current Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=15.369+30.797
+Other Current Liabilities+Current Deferred Liabilities
=2.071+0
=48.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Outlook Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Outlook Therapeutics Business Description

Traded in Other Exchanges
Address
111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Executives
Lawrence A Kenyon officer: CFO and Secretary C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin director ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Jeff Evanson officer: Chief Commercial Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Terry Dagnon officer: Chief Operating Officer C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Faisal Ghiath Sukhtian director 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger director 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii director, officer: CEO and President 1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian director, 10 percent owner 7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Syntone Ventures Llc 10 percent owner 1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman director 222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang director C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth director C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli director 4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments director C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007